All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC0107 | Human anti-BAIAP3 T cell receptor (AC7), pCDTCR1 | Human | AC7 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0108 | Human anti-BAIAP3 T cell receptor (AE5), pCDTCR1 | Human | AE5 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0109 | Human anti-BAIAP3 T cell receptor (BB2), pCDTCR1 | Human | BB2 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0110 | Human anti-BAIAP3 T cell receptor (BF5), pCDTCR1 | Human | BF5 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0111 | Human anti-BAIAP3 T cell receptor (FC12), pCDTCR1 | Human | FC12 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0112 | Human anti-BAIAP3 T cell receptor (IF9), pCDTCR1 | Human | IF9 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0113 | Human anti-BAIAP3 T cell receptor (JF6), pCDTCR1 | Human | JF6 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0114 | Human anti-BAIAP3 T cell receptor (LC3), pCDTCR1 | Human | LC3 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0115 | Human anti-BAIAP3 T cell receptor (ME3), pCDTCR1 | Human | ME3 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0116 | Human anti-BAIAP3 T cell receptor (NC8), pCDTCR1 | Human | NC8 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector | |
TCR-YC0117 | Human anti-BAIAP3 T cell receptor (NE8), pCDTCR1 | Human | NE8 | Human | ILNVDVFTL | HLA-A2 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION